glp 1 agonist black box warning The Dark Side of Ozempic The expanding landscape of GLP-1

C., Fernndez Land, L., Bergman, B

In the SUSTAIN-6 study, which compared subcutaneous semaglutide to placebo, DR complications occurred in 3% of semaglutide and 1.8% of placebo subjects

This may be similar to patients with diabetes with lower HbA1c having less change than those with higher HbA1c with anti-diabetes medications which dont cause hypoglycemia

Other medications that affect gastric motility (opioids, anticholinergics, prokinetics) should also be held per protocol

5 New Product Launches and Innovations The market for GLP-1 receptor agonists is also expanding due to continuous innovation in drug formulations and delivery methods

Each comes with its own dosing and indications